ALFA Filings
Every announcement, straight from the exchange
Every Jeena Sikho Lifecare other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
9 announcements with these filters
Jeena Sikho Lifecare Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as per regulatory requirements.
Jeena Sikho Lifecare received NABH accreditation for its hospital in Raipur, Chhattisgarh, signifying adherence to quality healthcare and patient safety standards.
Jeena Sikho Lifecare Limited informed shareholders about the web-link to access its 2025-26 Annual Report and 9th AGM Notice.
Jeena Sikho Lifecare announced the publication of six Ayurvedic research case studies in an international multidisciplinary journal. This highlights the company's ongoing commitment to clinical research.
Jeena Sikho Lifecare Ltd has filed its quarterly shareholding pattern disclosure as per SEBI regulations. This routine filing provides details of the company's equity distribution.
Jeena Sikho Lifecare Limited filed its Annual Secretarial Compliance Report for FY26. The report confirms overall regulatory adherence with minor observations regarding past disclosure delays.
Jeena Sikho Lifecare announced the publication of thirteen Ayurvedic case studies in international medical journals. This highlights the company's commitment to evidence-based clinical research and practice.
Jeena Sikho Lifecare Limited has appointed GoIndia Advisors LLP as its Investor Relations Management Agency. The agency will provide investor and public relations management services to the company. The appointment is effective from May 04, 2026, and aims to enhance the company's communication with the investor community.
Jeena Sikho Lifecare Limited announced the publication of seven case studies and two case reports in the Journal of Applied Science and Education. Authored by the company's medical professionals, these publications focus on Ayurvedic treatments for chronic kidney disease, sciatica, and osteoarthritis, highlighting the company's commitment to evidence-based clinical research.